SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joe E. who wrote (5281)9/9/1998 4:57:00 PM
From: Vector1  Read Replies (1) of 6136
 
I have no information on a Dupont acquisition. However, the question of how the tracking stock affects a potential acquition is quite interesting. I would think it would make the deal more attractive to Dupont. Dupont would essentially be buying AGPH General which with conservative assumptions on synergies it could do for well north of $40 per share and still be accretive. Moreover they would have a built in sales force for Sustiva and a second generation version of Sustiva in development. The tracking stock would not affect Duponts earnings and would create a nice tax writeoff.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News